Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Candel Therapeutics, Inc.

NASDAQ: CADL · Life Sciences · 3 alerts · CIK 1841387

Share price
$5.81Close, Nov 16
Market cap
$456M
Shares outstanding
78.45MLatest SEC cover page
Sector
Life Sciences
Industry
Biological Products, (No Diagnostic Substances)SIC 2836

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Candel Therapeutics, Inc. filings on SEC EDGAR ↗

4:11 PM ET 10-Q
Financial Results

Candel Therapeutics Q3 2026 Results: Net Loss of $21.9M, Loss Widens

Candel Therapeutics reported a significant increase in cash and cash equivalents to $203.1 million as of September 30, 2026, primarily driven by $142.6 million in net proceeds from public and at-the-market equity offerings. However, the company experienced a substantial increase in net loss to $69.6 million for the first nine months of 2026, compared to $8.7 million in the prior year, largely due to higher R&D spending and a negative swing in the fair value of warrant liabilities.

Key figure
Net loss $21.9M
4:06 PM ET 8-K
Financial Results

Candel Therapeutics Financial Results

Candel Therapeutics reported third quarter 2026 financial results, ending the period with $203.1 million in cash which is expected to fund operations into Q2 2028. The company updated its regulatory timeline, now planning to submit a Biologics License Application (BLA) for aglatimagene in prostate cancer in mid-2027 following assay refinement. Recent clinical progress included three poster presentations at the SITC 41st Annual Meeting showcasing data across its prostate, lung, and glioma programs.

Term
Q3 2026

“During the quarter we continued to execute well and make significant progress across the business, as we build the foundation to potentially become a commercial-stage biopharma company.”

Paul Peter Tak, M.D., Ph.D., FMedSci, President and CEO

“On the clinical side, we were honored to have had three posters accepted for presentation at SITC, featuring data on aglatimagene in localized prostate cancer and non-small cell lung cancer, and linoserpaturev in recurrent high-grade glioma. Together, the new biomarker data provide mechanistic support for the systemic effect and long-term clinical outcomes observed in our phase 3 trial of aglatimagene in patients with intermediate- to high-risk localized prostate cancer.”

Paul Peter Tak, M.D., Ph.D., FMedSci, President and CEO

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.